Literature DB >> 1707927

Determinant selection in murine experimental autoimmune myasthenia gravis. Effect of the bm12 mutation on T cell recognition of acetylcholine receptor epitopes.

A J Infante1, P A Thompson, K A Krolick, K A Wall.   

Abstract

C57BL/6 (B6) mice respond to immunization with acetylcholine receptor (AChR) from Torpedo californica as measured by T cell proliferation, antibody production, and the development of muscle weakness resembling human myasthenia gravis. The congenic strain B6.C-H-2bm12 (bm12), which differs from B6 by three amino acid substitutions in the beta-chain of the MHC class II molecule I-A, develops a T cell proliferative response but does not produce antibody or develop muscle weakness. By examining the fine specificity of the B6 and bm12 T cell responses to AChR by using T cell clones and synthetic AChR peptides, we found key differences between the two strains in T cell epitope recognition. B6 T cells responded predominantly to the peptide representing alpha-subunit residues 146-162; this response was cross-reactive at the clonal level to peptide 111-126. Based on the sequence homology between these peptides and the T cell response to a set of truncated peptides, the major B6 T cell epitope was determined to be residues 148-152. The cross-reactivity of peptides 146-162 and 111-126 could also be demonstrated in vivo. Immunization of B6 mice with either peptide primed for T cell responses to both peptides. In contrast, immunization of bm12 mice with peptide 111-126 primed for an anti-peptide response, which did not cross-react with 146-162. Peptide-reactive T cells were not elicited after immunization of bm12 mice with 146-162. These results define a major T cell fine specificity in experimental autoimmune myasthenia gravis-susceptible B6 mice to be directed at alpha-subunit residues 148-152. T cells from disease-resistant bm12 mice fail to recognize this epitope but do recognize other portions of AChR. We postulate that alpha-148-152 is a disease-related epitope in murine experimental autoimmune myasthenia gravis. In this informative strain combination, MHC class II-associated determinant selection, rather than Ag responsiveness per se, may play a major role in determining disease susceptibility.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1707927

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  6 in total

1.  Maintenance of immune tolerance to a neo-self acetylcholine receptor antigen with aging: implications for late-onset autoimmunity.

Authors:  Sue Stacy; Earlanda L Williams; Nathan E Standifer; Amanda Pasquali; Keith A Krolick; Anthony J Infante; Ellen Kraig
Journal:  J Immunol       Date:  2010-04-30       Impact factor: 5.422

Review 2.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

3.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice.

Authors:  Huan Yang; Elzbieta Goluszko; Chella David; David K Okita; Bianca Conti-Fine; Teh-sheng Chan; Mathilde A Poussin; Premkumar Christadoss
Journal:  J Clin Invest       Date:  2002-04       Impact factor: 14.808

4.  Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.

Authors:  P I Karachunski; N S Ostlie; D K Okita; B M Conti-Fine
Journal:  J Clin Invest       Date:  1997-12-15       Impact factor: 14.808

5.  C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells.

Authors:  Wei Wang; Monica Milani; Norma Ostlie; David Okita; Rajeev K Agarwal; Rachel R Caspi; Rachel Caspi; Bianca M Conti-Fine
Journal:  J Immunol       Date:  2007-06-01       Impact factor: 5.422

6.  A Novel Approach to Reinstating Tolerance in Experimental Autoimmune Myasthenia Gravis Using a Targeted Fusion Protein, mCTA1-T146.

Authors:  Alessandra Consonni; Sapna Sharma; Karin Schön; Cristina Lebrero-Fernández; Elena Rinaldi; Nils Yngve Lycke; Fulvio Baggi
Journal:  Front Immunol       Date:  2017-09-13       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.